{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:38:30Z","timestamp":1776487110008,"version":"3.51.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1053\/j.akdh.2024.11.004","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T13:12:26Z","timestamp":1743599546000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic Kidney Disease-Part 2: Management and Its Complications"],"prefix":"10.1053","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6374-837X","authenticated-orcid":false,"given":"Holly","family":"Kramer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.akdh.2024.11.004_bib1","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"13","key":"10.1053\/j.akdh.2024.11.004_bib2","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"issue":"15","key":"10.1053\/j.akdh.2024.11.004_bib3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/CIRCULATIONAHA.121.055329","article-title":"Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial","volume":"144","author":"Blumenthal","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1053\/j.akdh.2024.11.004_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.ajkd.2020.04.017","article-title":"Resistant hypertension in people with CKD: a review","volume":"77","author":"Fay","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.akdh.2024.11.004_bib5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/HYPERTENSIONAHA.116.08128","article-title":"Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014","volume":"68","author":"Hwang","year":"2016","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.akdh.2024.11.004_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jash.2013.06.004","article-title":"Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence","volume":"7","author":"Grigoryan","year":"2013","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"10.1053\/j.akdh.2024.11.004_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1524-6175.2005.04451.x","article-title":"Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?","volume":"7","author":"Khosla","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10008","key":"10.1053\/j.akdh.2024.11.004_bib8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"10208","key":"10.1053\/j.akdh.2024.11.004_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"4 Pt 1","key":"10.1053\/j.akdh.2024.11.004_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0895-7061(97)00491-3","article-title":"Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension","volume":"11","author":"Kassler-Taub","year":"1998","journal-title":"Am J Hypertens"},{"issue":"10","key":"10.1053\/j.akdh.2024.11.004_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.jhh.1000925","article-title":"ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension","volume":"13","author":"Mallion","year":"1999","journal-title":"J Hum Hypertens"},{"issue":"1","key":"10.1053\/j.akdh.2024.11.004_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/080370598437574","article-title":"The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan","volume":"7","author":"Andersson","year":"1998","journal-title":"Blood Press"},{"key":"10.1053\/j.akdh.2024.11.004_bib13","series-title":"2023 USRDS annual data report: epidemiology of kidney disease in the United States","year":"2023"},{"issue":"5","key":"10.1053\/j.akdh.2024.11.004_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100447","article-title":"Survival of older patients with advanced CKD managed without dialysis: a narrative review","volume":"4","author":"Chou","year":"2022","journal-title":"Kidney Med"},{"issue":"1","key":"10.1053\/j.akdh.2024.11.004_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12882-021-02516-6","article-title":"Does conservative kidney management offer a quantity or quality of life benefit compared to dialysis? A systematic review","volume":"22","author":"Buur","year":"2021","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2024.11.004_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181345","article-title":"Survival analysis of conservative vs. dialysis treatment of elderly patients with CKD stage 5","volume":"12","author":"Reindl-Schwaighofer","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.akdh.2024.11.004_bib17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.kint.2022.07.012","article-title":"Executive summary of the KDIGO 2022 clinical Practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"102","author":"Martin","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.11.004_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 clinical Practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"8","year":"2018","journal-title":"Kidney Int Suppl (2011)"},{"issue":"5S","key":"10.1053\/j.akdh.2024.11.004_bib19","first-page":"S1","article-title":"KDIGO 2022 clinical Practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1053\/j.akdh.2024.11.004_bib20","first-page":"S117","article-title":"KDIGO 2024 clinical Practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2024.11.004_bib21","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1046\/j.1523-1755.1999.00389.x","article-title":"Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients","volume":"55","author":"Fleischmann","year":"1999","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.akdh.2024.11.004_bib22","first-page":"702","article-title":"[Relationship between body mass index and all-cause mortality in hemodialysis patients: a meta-analysis]","volume":"51","author":"Wang","year":"2012","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"3","key":"10.1053\/j.akdh.2024.11.004_bib23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0735-1097(01)01448-6","article-title":"The relationship between obesity and mortality in patients with heart failure","volume":"38","author":"Horwich","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1053\/j.akdh.2024.11.004_bib24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/1055-9965.EPI-12-0485","article-title":"The role of obesity in cancer survival and recurrence","volume":"21","author":"Demark-Wahnefried","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1053\/j.akdh.2024.11.004_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.05700611","article-title":"Obesity and mortality risk among younger dialysis patients","volume":"7","author":"Hoogeveen","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2024.11.004_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242784","article-title":"Weighing the waitlist: weight changes and access to kidney transplantation among obese candidates","volume":"15","author":"Ku","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1053\/j.akdh.2024.11.004_bib28","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/ckj\/sfac090","article-title":"Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?","volume":"15","author":"Touzot","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.akdh.2024.11.004_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000527919","article-title":"Efficacy and safety of semaglutide, a glucagon-like peptide-1 receptor agonist in real-life: a case series of patients in maintenance incremental hemodialysis","volume":"12","author":"De la Flor","year":"2022","journal-title":"Case Rep Nephrol Dial"},{"issue":"2","key":"10.1053\/j.akdh.2024.11.004_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.akdh.2024.11.004_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10313","key":"10.1053\/j.akdh.2024.11.004_bib32","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.akdh.2024.11.004_bib33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1053\/j.akdh.2024.11.004_bib34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/ajt.15650","article-title":"Long-term outcomes in patients with obesity and renal disease after sleeve gastrectomy","volume":"20","author":"Kassam","year":"2020","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1053\/j.akdh.2024.11.004_bib35","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1007\/s00464-023-10200-z","article-title":"Comparative outcomes of bariatric surgery in patients with ESRD on dialysis in the modern era of renal transplantation: analysis using the 2015-2020 MBSAQIP database","volume":"37","author":"Alothman","year":"2023","journal-title":"Surg Endosc"},{"issue":"7","key":"10.1053\/j.akdh.2024.11.004_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamasurg.2020.0829","article-title":"Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease","volume":"155","author":"Sheetz","year":"2020","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1053\/j.akdh.2024.11.004_bib37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.soard.2017.01.005","article-title":"Laparoscopic sleeve gastrectomy: gateway to kidney transplantation","volume":"13","author":"Kienzl-Wagner","year":"2017","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"10.1053\/j.akdh.2024.11.004_bib38","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMra1505292","article-title":"Calciphylaxis","volume":"378","author":"Nigwekar","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.akdh.2024.11.004_bib39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ackd.2019.09.005","article-title":"Calciphylaxis: approach to diagnosis and management","volume":"26","author":"Seethapathy","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1053\/j.akdh.2024.11.004_bib40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ndt\/gfs548","article-title":"Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients","volume":"28","author":"Zitt","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2024.11.004_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ekir.2018.10.002","article-title":"Treatment of calciphylaxis in CKD: a systematic review and meta-analysis","volume":"4","author":"Udomkarnjananun","year":"2019","journal-title":"Kidney Int Rep"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T01:21:04Z","timestamp":1745025664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2949813924001836"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.11.004","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Kidney Disease-Part 2: Management and Its Complications","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}